Intec Pharma Ltd (NTEC) Shares Reduced by Renaissance Technologies LLC

Intec Pharma Ltd (NTEC) Shares Reduced by Renaissance Technologies LLC

Renaissance Technologies LLC decreased its stake in shares of Intec Pharma Ltd (NASDAQ:NTEC) by 51.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,100 shares of the biotechnology company’s stock after selling 45,798 shares during the period. Renaissance Technologies LLC’s holdings in Intec Pharma were worth $244,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. PNC Financial Services Group Inc. increased its holdings in Intec Pharma by 50.0% during the third quarter. PNC Financial Services Group Inc. now owns 75,000 shares of the biotechnology company’s stock valued at $424,000 after buying an additional 25,000 shares during the last quarter. ARK Investment Management LLC purchased a new stake in Intec Pharma during the third quarter valued at approximately $609,000. Migdal Insurance & Financial Holdings Ltd. increased its holdings in Intec Pharma by 13.0% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 589,996 shares of the biotechnology company’s stock valued at $3,333,000 after buying an additional 67,929 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. increased its holdings in Intec Pharma by 2,096.1% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 658,835 shares of the biotechnology company’s stock valued at $3,722,000 after buying an additional 628,835 shares during the last quarter. Institutional investors own 39.68% of the company’s stock.

Shares of NASDAQ NTEC opened at $7.88 on Tuesday. The firm has a market capitalization of $259.98 million, a PE ratio of -4.78 and a beta of 0.39. Intec Pharma Ltd has a 1 year low of $3.55 and a 1 year high of $8.78.

Intec Pharma (NASDAQ:NTEC) last announced its quarterly earnings data on Friday, November 9th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.03. As a group, research analysts anticipate that Intec Pharma Ltd will post -1.31 EPS for the current year.

A number of brokerages have commented on NTEC. Zacks Investment Research raised shares of Intec Pharma from a “sell” rating to a “hold” rating in a report on Tuesday. BidaskClub raised shares of Intec Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 8th. HC Wainwright set a $16.00 target price on shares of Intec Pharma and gave the company a “buy” rating in a report on Wednesday, October 24th. LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $12.00 target price on shares of Intec Pharma in a report on Tuesday, January 29th. Finally, Oppenheimer set a $15.00 price objective on shares of Intec Pharma and gave the stock a “buy” rating in a research note on Thursday, November 15th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Intec Pharma currently has a consensus rating of “Buy” and a consensus price target of $11.96.

Intec Pharma Company Profile

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

Further Reading: Trading Ex-Dividend Strategy

Want to see what other hedge funds are holding NTEC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intec Pharma Ltd (NASDAQ:NTEC).

Related posts

Leave a Comment